Standout Papers

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma 2018 2026 2020 2023 355
  1. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma (2018)
    Meletios Α. Dimopoulos, Dominik Dytfeld et al. New England Journal of Medicine

Immediate Impact

3 from Science/Nature 58 standout
Sub-graph 1 of 22

Citing Papers

From periphery to center stage: 50 years of advancements in innate immunity
2024 Standout
Multiple myeloma
2024 Standout
14 intermediate papers

Works of Naoki Takezako being referenced

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
2022
Prognostic Value of Sequencing-Based Minimal Residual Disease Detection in Multiple Myeloma
2014
and 6 more

Author Peers

Author Last Decade Papers Cites
Naoki Takezako 1149 829 715 100 1.8k
Selim Corbacioglu 1291 608 510 102 2.6k
Carlos Fernández de Larrea 1086 844 1133 130 2.1k
Anne Huynh 1575 580 608 127 2.6k
Olivier Decaux 1049 543 851 78 1.8k
Chan‐Jeoung Park 1184 563 553 183 2.3k
Sunil Abhyankar 1191 466 441 139 1.9k
Kyoo‐Hyung Lee 1612 724 524 167 2.5k
Julián Sevilla 1129 468 516 136 2.3k
Angela Michelutti 686 650 554 62 1.8k
Janet Cuttner 1380 688 603 86 2.6k

All Works

Loading papers...

Rankless by CCL
2026